293 related articles for article (PubMed ID: 17329034)
1. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
5. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S
Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
[TBL] [Abstract][Full Text] [Related]
7. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin.
Mahajan N; Bahl A; Dhawan V
Int J Cardiol; 2010 Jul; 142(3):273-8. PubMed ID: 19201044
[TBL] [Abstract][Full Text] [Related]
9. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
[TBL] [Abstract][Full Text] [Related]
10. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
11. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Takeuchi M
Med Hypotheses; 2006; 66(2):273-5. PubMed ID: 16216433
[TBL] [Abstract][Full Text] [Related]
12. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
13. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2007; 68(5):1096-8. PubMed ID: 17097822
[TBL] [Abstract][Full Text] [Related]
14. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
15. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
16. Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Ajith TA; Anu V; Riji T
J Exp Ther Oncol; 2008; 7(4):291-8. PubMed ID: 19227009
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2008 Aug; 71(2):259-61. PubMed ID: 18448262
[TBL] [Abstract][Full Text] [Related]
18. AGE, RAGE, and ROS in diabetic nephropathy.
Tan AL; Forbes JM; Cooper ME
Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
[TBL] [Abstract][Full Text] [Related]
19. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
Kanková K
Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
[TBL] [Abstract][Full Text] [Related]
20. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs).
Collison KS; Parhar RS; Saleh SS; Meyer BF; Kwaasi AA; Hammami MM; Schmidt AM; Stern DM; Al-Mohanna FA
J Leukoc Biol; 2002 Mar; 71(3):433-44. PubMed ID: 11867681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
